Novocure Limited (NVCR)

NASDAQ: NVCR · IEX Real-Time Price · USD
71.68
-0.35 (-0.49%)
Jun 29, 2022 12:36 PM EDT - Market open
-0.49%
Market Cap 7.50B
Revenue (ttm) 539.37M
Net Income (ttm) -36.54M
Shares Out 104.59M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE 909.09
Dividend n/a
Ex-Dividend Date n/a
Volume 141,405
Open 71.50
Previous Close 72.03
Day's Range 69.74 - 72.51
52-Week Range 56.39 - 225.40
Beta 0.88
Analysts Buy
Price Target 104.81 (+46.2%)
Earnings Date Aug 4, 2022

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cance... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Oct 2, 2015
CEO Asaf Danziger
Employees 1,167
Stock Exchange NASDAQ
Ticker Symbol NVCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is 104.81, which is an increase of 46.22% from the latest price.

Price Target
$104.81
(46.22% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Strength Seen in NovoCure (NVCR): Can Its 8% Jump Turn into More Strength?

NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Pat...

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a ...

Why Novocure Stock Is Plunging This Week

The broader stock market sell-off is pulling Novocure down.

3 Stocks That Could Help You Retire a Millionaire

All you need to reach a million dollars is some time, discipline, patience, and the right investments.

Other symbols: GOOGGOOGLTWLO

3 Stocks Down 50% or More That You Can Buy Right Now

Huge rebounds could be in store for these beaten-down stocks.

Other symbols: DNANVAX

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Ca...

ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NVCR #gastriccancer--Novocure and Zai Lab announced that the EF-31 phase 2 pilot study met its primary endpo...

3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030

A 5x return isn't a slam dunk with these stocks. But it's not a farfetched proposition.

Other symbols: MELITDOC

Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields...

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure has entered into a clinical trial collaboration agreement with MSD to study the use of Tumor Treating Fields concomitant with MSD's KEYTRUDA.

Nasdaq Bear Market: 3 Great Stocks to Buy That Are Down 50% or More

Their long-term prospects look great -- even if their current stock charts don't.

Other symbols: ALGNPYPL

3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030

These stocks are losers now. But they could be huge winners over the next few years.

Other symbols: CRSPDNA

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 76.47% and 1.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Novocure Reports First Quarter 2022 Financial Results

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a global oncology company working to extend surv...

The FDA Will Soon Give These 3 Healthcare Companies the Green Light

These Fool.com contributors see happy news in the future for Novavax, Axsome Therapeutics, and Novocure.

Other symbols: AXSMNVAX

Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure hosted a ceremonial groundbreaking with New Hampshire Governor Chris Sununu at Novocure's new flagship facility in Portsmouth, NH.

3 Stocks That Could Realistically Turn $300,000 Into $1 Million by 2030

There are clear paths for all of these companies to deliver huge returns to shareholders this decade.

Other symbols: IIPRMELI

Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR)...

This Up-and-Coming Healthcare Stock Could Skyrocket

Can Novocure gain widespread acceptance by physicians?

3 Biotech Stocks to Buy in April

They're good picks for very different reasons.

Other symbols: AMGNJAZZ

Novocure to Report First Quarter 2022 Financial Results

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial marke...

This Incredibly Promising Stock Will Trade Like a Volatile Biotech

This medical device company has major potential.

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Contro...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, wi...

Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields...

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #GynCSM--Novocure announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study of TTFields in ovarian cancer.

3 Biotech Stocks That Can Make You Richer in March (and Beyond)

These biotechs have promising near-term and long-term prospects.

Other symbols: AXSMVRTX

Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure's Founder and Chief Technology Officer, has been selected to receive the 2022 Israel Prize in the ...

Top 3 Cheap Healthcare Stocks You Shouldn't Ignore.

Some popular names in the healthcare sector have been down even by about 50% from their highs recently. But there are lots of opportunities in this sector.

Other symbols: HIMSTDOC